Research Divisions

Haematological Malignancies

Group LeaderLocation and ContactMembersHistory of the GroupLines of ResearchNotable PublicationsProjectsPhD ThesesClinical TrialsPatents and TrademarksNews

Teresa Bernal del Castillo

  • Consultant, Haematology and Haemotherapy Department, Hospital Universitario Central de Asturias (HUCA).
  • Associate Lecturer, Universidad de Oviedo.

Servicio de Hematología y Hemoterapia, HUCA.

Avda. Hospital Universitario s/n, Oviedo, Spain.

 

E-mail: bernalmaria@uniovi.es

Name Position Organisation
Teresa Bernal del Castillo Principal Investigator HUCA
Enrique Colado Varela Specialist Health Professional (FEA), Haematology and Haemotherapy Department HUCA
Sara Alonso Álvarez FEA, Haematology and Haemotherapy Department HUCA
Laura Vilorio Marqués Postdoctoral Researcher ISPA
Ainhoa Fernández Moreno FEA, Haematology and Haemotherapy Department HUCA
Dejan Golijanin Medicine student Universidad de Oviedo
Roberto Prieto Colella Medicine student Universidad de Oviedo
Fernando Menéndez Menéndez Medicine student Universidad de Oviedo
  1. Supportive treatment in patients undergoing intensive chemotherapy procedures or haematopoietic cell transplantation (HCT), or receiving hypomethylating drugs.
  2. Prognostic stratification of myeloid malignancies.
  3. Development and application of new drugs.
  4. Effectiveness of treatments available for haematological malignancies: clinical and preclinical phases.
  • Motlló C, Ribera JM, Morgades M, Granada I, Montesinos P, Brunet S, Bergua J, Tormo M, García-Boyero R, Sarrà J, Del Potro E, Grande C, Barba P, Bernal T, Amigo ML, Grau J, Cervera J, Feliu E; PETHEMA Group, Spanish Society of Hematology.. Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols. Leuk Lymphoma. 2017 Jan;58(1):145-152.
  • Amado-Rodríguez L, Bernal T, López-Alonso I, Blázquez-Prieto J, García-Prieto E, Albaiceta GM. Impact of Initial Ventilatory Strategy in Hematological Patients With Acute Respiratory Failure: A Systematic Review and Meta-Analysis. Crit Care Med. 2016 Jul;44(7):1406-13.
  • Osorio FG, Soria-Valles C, Santiago-Fernández O, Bernal T, Mittelbrunn M, Colado E, Rodríguez F, Bonzon-Kulichenko E, Vázquez J, Porta-de-la-Riva M, Cerón J, Fueyo A, Li J, Green AR, Freije JM, López-Otín C. Loss of the proteostasis factor AIRAPL causes myeloid transformation by deregulating IGF-1 signaling. Nat Med. 2016 Jan;22(1):91-6.
  • Ribera JM, García O, Oriol A, Gil C, Montesinos P, Bernal T, González-Campos J, Lavilla E, Ribera J, Brunet S, Martínez MP, Tormo M, Genescà E, Barba P, Sarrà J, Monteserín MC, Soria B, Colorado M, Cladera A, García-Guiñón A, Calbacho M, Serrano A, Ortín X, Pedreño M, Amigo ML, Escoda L, Feliu E; PETHEMA Group, Spanish Society of Hematology.. Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group. Leuk Res. 2016 Feb;41:12-20.
  • Xicoy B, Germing U, Jimenez MJ, Garcia O, Garcia R, Schemenau J, Pedro C, Luño E, Bernal T, González B, Strupp C, Ardanaz M, Kuendgen A, Cedena MT, Neukirchen J, Calabuig M, Brunet S, Medina A, Amigo ML, Ramos F, Callejas M, Díez-Campelo M, Bailén A, Collado R, Vicente A, Arnan M, Valcarcel D, Arilla MJ, Zamora L, Benlloch L, Sanz G. Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia. Eur J Haematol. 2016 Jul;97(1):33-8.
  • Kelleher N, Gallardo D, González-Campos J, Hernández-Rivas JM, Montesinos P, Sarrá J, Gil C, Barba P, Guàrdia R, Brunet S, Bernal T, Martínez MP, Abella E, Bermúdez A, Sánchez-Delgado M, Antònia C, Gayoso J, Calbacho M, Ribera JM; Pethema Group, Spanish Society of Hematology.. Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy. Leuk Lymphoma. 2016;57(1):86-91.
  • Falantes J, Delgado RG, Calderón-Cabrera C, Márquez-Malaver FJ, Valcarcel D, de Miguel D, Bailén A, Bargay J, Bernal T, González-Porras JR, Tormo M, Ramos F, Andreu R, Xicoy B, Nomdedeu B, Brunet S, Sánchez J, Jurado AF, Bonanad S, Pérez-Simón JA, Sanz G; Spanish Group of Myelodysplastic Syndromes (GESMD). Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score. Leuk Res. 2015 Jan;39(1):52-7.
  • Díez Campelo M, Sánchez-Barba M, de Soria VG, Martino R, Sanz G, Insunza A, Bernal T, Duarte R, Amigo ML, Xicoy B, Tormo M, Iniesta F, Bailén A, Benlloch L, Córdoba I, López-Villar O, Del Cañizo MC; Spanish Registry of MDS.. Results of allogeneic stem cell transplantation in the Spanish MDS registry: prognostic factors for low risk patients. Leuk Res. 2014 Oct;38(10):1199-206.
  • Motlló C, Ribera JM, Morgades M, Granada I, Montesinos P, González-Campos J, Fernández-Abellán P, Tormo M, Bethencourt C, Brunet S, Hernández-Rivas JM, Moreno MJ, Sarrà J, Del Potro E, Barba P, Bernal T, Grande C, Grau J, Cervera J, Feliu E; PETHEMA Group, Spanish Society of Hematology.. Prognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols. Cancer. 2014 Dec 15;120(24):3958-64.
  • Briones J, Novelli S, García-Marco JA, Tomás JF, Bernal T, Grande C, Canales MA, Torres A, Moraleda JM, Panizo C, Jarque I, Palmero F, Hernández M, González-Barca E, López D, Caballero D; Grupo Español de Linfomas y Trasplante Autologo de Médula Ósea (GELTAMO).. Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial. Haematologica. 2014 Jul;99(7):e126.
  • Bernal T, Diez-Campelo M, Godoy V, Rojas S, Colado E, Alcoceba M, González M, Vidriales B, Sánchez-Guijo FM, López-Corral L, Luño E, del Cañizo C. Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome. Leuk Res. 2014 May;38(5):551-6.
  • Bernal T, Pardavila EV, Bonastre J, Jarque I, Borges M, Bargay J, Ayestarán JI, Insausti J, Marcos P, González-Sanz V, Martínez-Camblor P, Albaiceta GM. Survival of hematological patients after discharge from the intensive care unit: a prospective observational study. Crit Care. 2013 Dec 30;17(6):R302.
  • Briones J, Novelli S, García-Marco JA, Tomás JF, Bernal T, Grande C, Canales MA, Torres A, Moraleda JM, Panizo C, Jarque I, Palmero F, Hernández M, González-Barca E, López D, Caballero D; GELTAMO.. Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial. Haematologica. 2014 Mar;99(3):505-10.
  • Xicoy B, Jiménez MJ, García O, Bargay J, Martínez-Robles V, Brunet S, Arilla MJ, Pérez de Oteyza J, Andreu R, Casaño FJ, Cervero CJ, Bailén A, Díez M, González B, Vicente AI, Pedro C, Bernal T, Luño E, Cedena MT, Palomera L, Simiele A, Calvo JM, Marco V, Gómez E, Gómez M, Gallardo D, Muñoz J, de Paz R, Grau J, Ribera JM, Benlloch LE, Sanz G. Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes. Leuk Lymphoma. 2014 Jun;55(6):1300-3.
  • Ribera JM, García O, Grande C, Esteve J, Oriol A, Bergua J, González-Campos J, Vall-Llovera F, Tormo M, Hernández-Rivas JM, García D, Brunet S, Alonso N, Barba P, Miralles P, Llorente A, Montesinos P, Moreno MJ, Hernández-Rivas JÁ, Bernal T. Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab). Cancer. 2013 May 1;119(9):1660-8.
  • Urdinguio RG, Fernandez AF, Moncada-Pazos A, Huidobro C, Rodriguez RM, Ferrero C, Martinez-Camblor P, Obaya AJ, Bernal T, Parra-Blanco A, Rodrigo L, Santacana M, Matias-Guiu X, Soldevilla B, Dominguez G, Bonilla F, Cal S, Lopez-Otin C, Fraga MF. Immune-dependent and independent antitumor activity of GM-CSF aberrantly expressed by mouse and human colorectal tumors. Cancer Res. 2013 Jan 1;73(1):395-405.
  • Bernal T, Moncada-Pazos A, Soria-Valles C, Gutiérrez-Fernández A. Effects of azacitidine on matrix metalloproteinase-9 in acute myeloid leukemia and myelodysplasia. Exp Hematol. 2013 Feb;41(2):172-9.
  • Nadeu F, Delgado J, Royo C, Baumann T, Stankovic T, Pinyol M, Jares P, Navarro A, Martín-García D, Beà S, Salaverria I, Oldreive C, Aymerich M, Suárez-Cisneros H, Rozman M, Villamor N, Colomer D, López-Guillermo A, González M, Alcoceba M, Terol MJ, Colado E, Puente XS, López-Otín C, Enjuanes A, Campo E. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. Blood. 2016 Apr 28;127(17):2122-30.
  • Puente XS, Beà S, Valdés-Mas R, Villamor N, Gutiérrez-Abril J, Martín-Subero JI, Munar M, Rubio-Pérez C, Jares P, Aymerich M, Baumann T, Beekman R, Belver L, Carrio A, Castellano G, Clot G, Colado E, Colomer D, Costa D, Delgado J, Enjuanes A, Estivill X, Ferrando AA, Gelpí JL, González B, González S, González M, Gut M, Hernández-Rivas JM, López-Guerra M, Martín-García D, Navarro A, Nicolás P, Orozco M, Payer ÁR, Pinyol M, Pisano DG, Puente DA, Queirós AC, Quesada V, Romeo-Casabona CM, Royo C, Royo R, Rozman M, Russiñol N, Salaverría I, Stamatopoulos K, Stunnenberg HG, Tamborero D, Terol MJ, Valencia A, López-Bigas N, Torrents D, Gut I, López-Guillermo A, López-Otín C, Campo E. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature. 2015 Oct 22;526(7574):519-24.
  • Paiva B, Chandia M, Vidriales MB, Colado E, Caballero-Velázquez T, Escalante F, Garcia de Coca A, Montes MC, Garcia-Sanz R, Ocio EM, Mateos MV, San Miguel JF. Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma. Blood. 2014 Aug 21;124(8):1300-03.
  • Ocio EM, Dávila J, Caballero JC, Alonso S, de la Calle VG, García-Sanz R, Gazi L, Opio S, Jiménez M, San-Miguel JF, Mateos MV. Evidence of long-term disease control with panobinostat maintenance in patients with relapsed multiple myeloma. Haematologica. 2015 Jul;100(7):e289-91.

The impact of azacitidine on major supportive treatment and standard treatment in patients with MDS -intermediate 2 and high in routine clinical practice.

  • Principal Investigator: Teresa Bernal del Castillo
  • Sociedad Española de Hematología y Hemoterapia (Spanish Society of Haematology and Haemotherapy) - Spanish Myelodysplastic Syndromes Group, 2014-2015
  • TRC 112121. A randomised, double-blind, placebo-controlled, Phase III, multi-centre study of eltrombopag or placebo in combination with azacitidine in subjects with IPSS intermediate-1, intermediate-2 and high risk myelodysplastic syndromes (MDS). EUDRACT Code 2013-000918-37
  • A phase 3, double-blind, randomised study to compare the efficacy and safety ofluspatercept (ACE-536) versus placebo for the treatment of anaemia due to ipss-r very low, low, or intermediate risk myelodysplastic syndromes in subjects with ring sideroblasts who require red blood cell transfusions. EUDRACT Code 2015-003454-41
  • SGI-110-04. A phase 3, multicentre, open-label, randomised study of SGI-110 versus treatment choice (TC) in adults with previously untreated acute myeloid leukaemia (AML) who are not considered candidates for intensive remission induction chemotherapy. EUDRACT Code 2014-001233-89
  • CC-486-AML-001. EUDRACT Code 2012-003457-28 . A phase 3, randomised, double-blind, placebo-controlled study to compare efficacy and safety of oral azacitidine plus best supportive care versus best supportive care as maintenance therapy in subjects with acute myeloid leukaemia in complete remission . EUDRACT Code 2014-001233-89
  • AZA-AML-001. EUDRACT Code 2009-012346-23. A Phase 3, Multicentre, Randomised, Open-label, Study of Azacitidine (Vidaza®) Versus Conventional Care Regimens for the Treatment of Older Subjects With Newly Diagnosed Acute Myeloid Leukaemia
  • 04-21. EUDRACT Code 2010-019755-21. A Phase III, Multi-Centre, Randomised, Controlled Study to Assess the Efficacy and Safety of ON 01910.Na Administered as a 72-Hour Continuous Intravenous Infusion Every Other Week in Myelodysplastic Syndrome Patients with Excess Blasts Relapsing After, or Refractory to, or Intolerant to Azacitidine or Decitabine
  • SINTRA-REV. NIH (US) Code NCT01243476 . Multicentre, Randomised, Double-blind, Phase III Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) With Alteration in 5q- and Anaemia Without the Need of Transfusion